Switching Lens Designs May Sustain Myopia Control in Children

Myopia in children has become a pressing global health problem. The condition is appearing earlier and more frequently than it did a generation ago, and when it takes hold during childhood, it sets the stage for serious eye damage later in life. The eye grows too long, and that excess elongation can lead to irreversible vision loss in adulthood—complications that are difficult or impossible to reverse once they take root.

Optical interventions have offered some hope. Specialized contact lenses and spectacle lenses designed to slow myopia progression do work, at least initially. But researchers have noticed a troubling pattern: the benefit tends to fade after the first year. One theory is that the retina adapts to the optical signals the lens sends, essentially becoming accustomed to the correction and losing its protective effect over time. This raises a practical question: what if you changed the lens design partway through treatment? Could switching the optical signal prevent that adaptation and keep the treatment working longer?

A team from Wenzhou Medical University and collaborating institutions set out to test this idea. They enrolled 218 children between ages six and twelve in a two-year randomized trial, published in Eye and Vision in 2025. The children wore Lenslet-Array-Integrated spectacle lenses—LARI lenses—which are designed with tiny lenslets of either positive or negative power embedded in the lens. The key innovation was comparing children who stuck with the same lens design throughout the study against those who switched from one design to the other after one year.

The results were striking in one dimension and modest in another. Over two years, children wearing LARI lenses showed substantially less eye elongation than would be expected with conventional single-vision glasses. The average axial elongation—the lengthening of the eyeball itself—ranged from 0.33 to 0.44 millimeters across the LARI groups. That is markedly lower than what researchers extrapolated for a control group wearing standard lenses. The protective effect on the refractive error itself, the measure of how much the eye's focusing power had shifted, weakened during the second year. But the suppression of eye elongation held up.

When the researchers looked at the switching strategy specifically, they found something encouraging. Children who switched lens designs after year one showed less axial elongation during the second year than would be expected if they had simply continued wearing conventional glasses. Yet switching did not produce any additional benefit in terms of refractive error progression—the children who switched and those who stayed with the same design showed similar changes in that measure.

The findings suggest that myopia control works through mechanisms more complex than the standard optical defocus theory would predict. Both the positive and negative lenslet designs produced comparable modulation of the retinal image, which may explain why they had similar overall effects despite their opposite powers. More importantly, the data hint that alternating the optical signals sent to the eye may help counteract the decline in treatment effectiveness that typically emerges with prolonged use of a single intervention.

One of the senior investigators noted that the study represents a shift in thinking about long-term myopia management. Rather than applying the same optical strategy year after year, adjusting the visual signals the eye receives may help sustain the structural benefits—particularly the slowing of eye growth. While switching lens designs did not further reduce refractive error progression, the continued suppression of axial elongation matters clinically, because eye length is directly linked to the risk of pathological myopia and vision-threatening complications in adulthood.

For clinicians, the findings offer a practical tool. Children who show diminishing responsiveness to a single optical intervention over time may benefit from switching lens designs, a strategy that maintains the structural benefit of slowing eye elongation without adding burden to the treatment regimen. Lens switching alone may not fully prevent refractive progression, but it could be combined with other approaches—low-dose atropine or orthokeratology, for instance—to achieve stronger control. The study supports a dynamic, adaptive approach to myopia management, one that acknowledges the eye's capacity to adapt biologically and prioritizes the long-term structural outcomes that matter most for preserving vision across a lifetime.